BIB - ProShares Ultra Nasdaq Biotechnology
| Previous Close | 48.80 |
| Open | 48.50 |
| Bid | 48.17 x 800 |
| Ask | 48.21 x 800 |
| Day's Range | 48.15 - 48.75 |
| 52 Week Range | 36.05 - 70.82 |
| Volume | 55,856 |
| Avg. Volume | 118,357 |
| Net Assets | 203.54M |
| NAV | 48.76 |
| PE Ratio (TTM) | N/A |
| Yield | 0.00% |
| YTD Return | 14.97% |
| Beta (3Y Monthly) | 2.66 |
| Expense Ratio (net) | 0.95% |
| Inception Date | 2010-04-06 |
- Investopedia
BIB Versus LABU: Comparing Leveraged Biotech ETFs
Read a comparison of BIB and LABU and a description of the characteristics and historical performance of these leveraged biotech ETFs.
- Zacks
Biotech ETFs in Focus on String of Q1 Earnings Beats
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
- Zacks
Will Biotech ETFs Continue to Rally in Q1 Earnings?
Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .
- Investor's Business Daily
Swing Trade In Biotech Sector Gave The Best Of Both Worlds
Stocks in the biotech sector pose a problem for a swing trade. We take profits quicker, so we need to avoid big losses. Biotech stocks make that difficult.
- Market Realist
Major Biotech ETFs Had Lackluster Performance in the Past Month
All three major biotechnology ETFs—the SPDR S&P Biotech ETF (XBI), the iShares NASDAQ Biotechnology Index (IBB), and the ProShares Ultra Nasdaq Biotechnology ETF (BIB)—have posted returns of ~1% in last month, starting on August 10. That compares unfavorably with the performance of the SPDR S&P 500 ETF (SPY), which returned ~1.7% in the same period.
